FBR Capital Reiterates an 'Outperform' on CapLease (LSE); Slight 2Q11 Estimate Change
Tweet
Share
E-mailGet Alerts LSE Hot Sheet
Price: $8.53 --0%
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
FBR Capital reiterates an 'Outperform' on CapLease (NYSE: LSE), PT $7.
FBR analyst says, "We are lowering our 2Q11 FFO estimate to $0.15 from $0.16. The decline can be primarily attributable to a higher cash balance in 2Q11 from CapLease's $16 million sale of two first-mortgage loans subsequent to 1Q11. Our 2011 "core" FFO estimate of $0.66 compares to management's guidance of $0.65–$0.70. Our 2012 FFO estimate of $0.75/share is unchanged."
For more ratings news on CapLease click here and for the rating history of CapLease click here.
Shares of CapLease closed at $4.95 yesterday.
FBR analyst says, "We are lowering our 2Q11 FFO estimate to $0.15 from $0.16. The decline can be primarily attributable to a higher cash balance in 2Q11 from CapLease's $16 million sale of two first-mortgage loans subsequent to 1Q11. Our 2011 "core" FFO estimate of $0.66 compares to management's guidance of $0.65–$0.70. Our 2012 FFO estimate of $0.75/share is unchanged."
For more ratings news on CapLease click here and for the rating history of CapLease click here.
Shares of CapLease closed at $4.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amazon.com (AMZN) PT Raised to $215 at UBS
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
